News headlines about Galena Biopharma (NYSE:SLS) have been trending positive recently, Accern Sentiment reports. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Galena Biopharma earned a daily sentiment score of 0.28 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 44.2934986420708 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
NYSE:SLS traded down $0.51 on Friday, reaching $5.62. 228,770 shares of the company’s stock were exchanged, compared to its average volume of 482,874. Galena Biopharma has a 52 week low of $3.43 and a 52 week high of $19.80.
Separately, HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of Galena Biopharma in a research report on Monday, April 2nd.
About Galena Biopharma
Receive News & Ratings for Galena Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galena Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.